Legorreta Pablo G. 4

What Happened
Pablo G. Legorreta, CEO, Chairman and a Director of Royalty Pharma plc (RPRX), was granted/received 143,821 Class A ordinary shares on 2026-05-06 as the settlement of Equity Performance Awards. The shares were issued at $0.00 per share (no cash paid) and the acquisition was reported as exempt under Rule 16b-3.

Key Details

• Transaction date: 2026-05-06; Form 4 filed 2026-05-08 (appears timely — within the usual two-business-day window).
• Shares: 143,821 Class A ordinary shares; Price: $0.00 (award/settlement).
• Footnote: Exempt acquisition pursuant to Rule 16b-3 in connection with settlement of Equity Performance Awards.
• Shares owned after the transaction: not specified in the information provided.
• Additional holdings disclosed: Reporting person and family vehicles hold limited partnership interests exchangeable into 73,495,660 Class A ordinary shares and Class E ordinary shares of RPH exchangeable into 13,356,742 Class A shares; Class E shares are subject to vesting conditions.

Context
This was an equity award/settlement as part of compensation, not an open-market purchase or sale—such grants are common for executives and do not by themselves indicate buying or selling sentiment. The filing notes large exchangeable interests held by the reporting person and family vehicles, which represent substantial potential indirect exposure to RPRX shares (some subject to vesting).